10-Q: Movano Inc. Reports Third Quarter 2024 Results, Revenue Growth Driven by Evie Ring Sales

Movano Inc. reported a net loss of $7.2 million for the third quarter of 2024, with revenue of $0.1 million driven by sales of the Evie Ring.

Summary

• Movano Inc. reported a net loss of $7.2 million for the three months ended September 30, 2024, compared to a net loss of $9.0 million for the same period in 2023.
• The company's revenue for the third quarter of 2024 was $0.1 million, a significant increase from no revenue in the same period of 2023, due to the commercialization of the Evie Ring.
• For the nine months ended September 30, 2024, Movano reported a net loss of $19.1 million, compared to a net loss of $23.3 million for the same period in 2023.
• Revenue for the first nine months of 2024 totaled $0.9 million, compared to no revenue in the same period of 2023.
• Research and development expenses decreased to $3.4 million in Q3 2024 from $5.6 million in Q3 2023, and to $9.2 million for the nine months ended September 30, 2024, from $13.7 million for the same period in 2023.
• Sales, general, and administrative expenses decreased to $3.2 million in Q3 2024 from $3.4 million in Q3 2023, and to $8.8 million for the nine months ended September 30, 2024, from $10.0 million for the same period in 2023.
• As of September 30, 2024, Movano had $11.3 million in cash and cash equivalents.
• The company completed a 1-for-15 reverse stock split on October 29, 2024.
• Movano is developing the EvieMED Ring and a System-on-a-Chip for blood pressure and glucose monitoring.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in revenue generation and cost control, the company's significant losses, limited cash runway, and dependence on future capital raises create substantial uncertainty. The material weakness in internal controls is also a concern.

Positives

• Movano successfully launched and began generating revenue from the Evie Ring, with $0.1 million in revenue in Q3 2024 and $0.9 million for the nine months ended September 30, 2024.
• The company's net loss decreased in both the third quarter and the first nine months of 2024 compared to the same periods in 2023.
• Research and development expenses decreased significantly, indicating improved cost management.
• Sales, general, and administrative expenses also decreased, further demonstrating cost control.
• The company secured $24.1 million in gross proceeds through a private placement in April 2024, strengthening its financial position.
• Movano has made progress in developing its EvieMED device and is pursuing FDA clearance.

Negatives

• Movano continues to incur significant net losses, with a $7.2 million loss in Q3 2024 and a $19.1 million loss for the nine months ended September 30, 2024.
• The company's cash and cash equivalents of $11.3 million are not expected to be sufficient to fund operations for the next twelve months.
• The company has a history of losses and negative cash flows from operations since its inception.
• Movano is dependent on raising additional capital to fund its future operations.
• The company has identified a material weakness in its internal control over financial reporting.

Risks

• Movano's ability to continue as a going concern is dependent on its ability to obtain additional funding.
• The company faces risks related to the development and commercialization of its products, including regulatory approvals.
• There is a risk that the company may not be able to achieve profitability.
• The company is dependent on third-party manufacturers and suppliers.
• Movano faces competition from other companies in the wearable health technology market.
• The company's stock price could be negatively affected by a failure to meet Nasdaq's continued listing requirements.
• The company has identified a material weakness in its internal control over financial reporting, which could lead to misstatements in financial reports.

Future Outlook

Movano expects to continue to incur significant expenses and increasing operating losses for at least the next several years. The company anticipates that its expenses will increase substantially as it advances the development of its products, prepares for marketing approvals, and develops its plans for manufacturing, distributing, and marketing its products. The company expects to finance future cash needs through public or private equity offerings, debt financings, or corporate collaborations and licensing arrangements.

Management Comments

• The company is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices.
• The company launched the Evie Ring as a general wellness device without any FDA premarket clearances.
• The company is planning to seek FDA clearances on its medical device, which will be sold under the brand name EvieMED.
• The company believes that FDA clearance of these metrics, sold via prescription under the brand name EvieMED, would foster clinical-level confidence in EvieMEDs monitoring capabilities.
• The company is currently conducting clinical trials with the SoC and developing algorithms that, if successful, will enable us to develop wearables that can monitor glucose non-invasively and blood pressure without a cuff.

Industry Context

Movano is operating in the rapidly growing wearable health technology market. The company's focus on women's health with the Evie Ring and its development of non-invasive monitoring technologies for glucose and blood pressure position it to potentially capture a significant share of this market. The company's pursuit of FDA clearances for its medical devices is a key differentiator from some competitors that focus on general wellness devices.

Comparison to Industry Standards

• Movano's revenue of $0.9 million for the first nine months of 2024 is relatively low compared to established wearable technology companies like Fitbit (now part of Google) or Apple, which generate billions in revenue annually.
• The company's net losses are typical for early-stage technology companies that are investing heavily in research and development and commercialization efforts. For example, companies like Dexcom, which focuses on continuous glucose monitoring, also experienced significant losses in their early years before achieving profitability.
• Movano's focus on FDA-cleared medical devices is a different approach than some competitors that focus on general wellness devices. This approach could lead to higher barriers to entry but also greater market potential in the long term.
• The company's development of a System-on-a-Chip for non-invasive glucose and blood pressure monitoring is a significant technological advancement that could give it a competitive edge over companies that rely on traditional methods.
• Compared to companies like Oura, which also focuses on ring-based wearables, Movano's Evie Ring is specifically designed for women, which could give it a niche market advantage.
• The company's cash position of $11.3 million is relatively low compared to larger, more established companies, highlighting the need for additional capital raises.

Related Party Transactions

• Certain directors and officers participated in the April 2024 private placement, purchasing 19,168 units at an offering price of $8.48 per unit.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or changes in the company's operations.
• Customers may benefit from the company's innovative products, but there is a risk of delays or changes in product availability.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• The company will continue to advance the engineering design and development of the Evie Ring and other potential products.
• The company will prepare applications required for marketing approval of the Evie Ring in the United States.
• The company will develop its plans for manufacturing, distributing, and marketing the Evie Ring and other potential products.
• The company will add operational, financial, and management information systems and personnel.
• The company will continue to conduct clinical trials with the SoC and develop algorithms for non-invasive glucose and blood pressure monitoring.

Key Dates

Keywords

Evie Ring, wearable technology, FDA clearance, medical devices, health monitoring, financial results, reverse stock split, capital raise, net loss, revenue, research and development, stock warrants, private placement, going concern